12 results
Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series

Thumbnail

D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"

Thumbnail

D3.418 - Modulation of Mast Cell Activation by Histamine H3 and H4 Receptor Antagonists

Thumbnail

D3.420 - IL-1β, IL-6, and TNF serum levels in mastocytosis are not correlated with psychometric measures, though they correlate to serum tryptase and recurrent edemas

Thumbnail

D3.422 - Evaluating Elevated Baseline Mast Cell Tryptase: Insights from an Adult Allergy Service

Thumbnail

D1.324 - Evaluation of the Potential for Sebetralstat to Cause Pseudo-allergic Reactions